TG Therapeutics Announces Final Long-Term Results From Phase 3 GENUINE Study Of Ublituximab In Combination With Ibrutinib In Patients With High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia
Benzinga Newsdesk